Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population-Level Resources and Costs Associated with Low-Risk Prostate Cancer Patients on Active Surveillance.

Cancers·2026
Same author

Palliative care, socioeconomic position, and end-of-life cancer quality outcomes: a mediation analysis.

EClinicalMedicine·2026
Same author

Developing an expert consensus statement on emergency preparedness for cancer care delivery in Canada: a modified Delphi study.

Archives of public health = Archives belges de sante publique·2026
Same author

Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
Same author

Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Updated breast cancer costs for women by disease stage and phase of care using population-based databases.

Health reports·2024
Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026
Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026
Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026
Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026
Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026
Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

Advancing performance measurement in oncology.

Francis X Campion1, Leanne R Larson, Pamela J Kadlubek

  • 1Outcome Sciences, 201 Broadway, 5th Floor, Cambridge, MA 02139, USA. fxcampion@outcome.com

The American Journal of Managed Care
|June 30, 2011
PubMed
Summary
This summary is machine-generated.

The American Society of Clinical Oncology's Quality Oncology Practice Initiative (QOPI) improves cancer care quality. Repeat participants show better pain management and end-of-life care discussions, enhancing patient value.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: May 31, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Oncology
  • Healthcare Quality Improvement
  • Health Services Research

Background:

  • The US healthcare system faces pressure to enhance patient outcomes and reduce costs.
  • Government payers seek private sector partnerships for quality measurement and healthcare value improvement.
  • The American Society of Clinical Oncology (ASCO) developed the Quality Oncology Practice Initiative (QOPI) in 2006 to promote quality cancer care.

Purpose of the Study:

  • To evaluate the impact of the Quality Oncology Practice Initiative (QOPI) on cancer care quality.
  • To assess the association between participation duration in QOPI and performance on key quality metrics.
  • To examine QOPI's role in improving end-of-life care within oncology practices.

Main Methods:

  • QOPI is a voluntary, physician-led, practice-based quality improvement program.
  • It utilizes performance measurement and benchmarking among US oncology practices.
  • Data from multiple QOPI data collection cycles were analyzed, comparing repeat participants with first-time participants.

Main Results:

  • Practices with multiple QOPI data collection cycles demonstrated superior performance in pain management (62.61% vs 46.89%).
  • Repeat QOPI participants showed significantly better documentation of hospice and palliative care discussions (62.42% vs 54.65%).
  • Higher rates of hospice enrollment were observed among experienced QOPI participants.

Conclusions:

  • The Quality Oncology Practice Initiative (QOPI) is an effective system for measuring and improving cancer care quality.
  • Sustained participation in performance measurement programs like QOPI is linked to enhanced patient outcomes, particularly in end-of-life care.
  • QOPI exemplifies how robust performance measurement can drive improvements in the quality and value of cancer care.